USPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's beginner investment knowledge, long-term strategy, and available capital, USPH is not a strong buy at the moment. The company's recent financial performance shows declining net income and EPS, and the technical indicators suggest a bearish trend. Additionally, no significant positive trading signals or catalysts are present to justify immediate investment.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 34.026, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support levels (S1: 74.882, S2: 73.693), with resistance levels at R1: 78.728 and R2: 79.917. Overall, the technical setup indicates a bearish trend.
Jefferies assumes a Buy rating with a price target of $102, citing strategic hospital alliances and improved Medicare rates that could drive organic growth and margin expansion.
The stock is down 1.55% in pre-market trading, and financial performance in Q4 2025 showed a significant decline in net income (-182.87% YoY) and EPS (-182.69% YoY). No recent insider or hedge fund activity indicates a lack of strong institutional confidence.
In Q4 2025, revenue increased by 12.35% YoY to $202.73M. However, net income dropped significantly to -$6.55M (-182.87% YoY), and EPS fell to -0.43 (-182.69% YoY). Gross margin improved to 20.65% (+7.61% YoY), but overall profitability remains a concern.
Jefferies recently assumed coverage with a Buy rating and a price target of $102, revised down from $110. Analysts highlight potential growth from strategic hospital alliances and improved Medicare rates but acknowledge challenges in achieving these targets.
